Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have identified glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, obesity and nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).

Beijing Earthwise Technology Co. Ltd. has synthesized E3 ubiquitin-protein ligase CBL-B inhibitors reported to be useful for the treatment of cancer.

Adcentrx Therapeutics Inc. and Adcentrx Therapeutics Shanghai Co. Ltd. have disclosed antibody-drug conjugates comprising a monoclonal antibody covalently bound to a cytotoxic drug through a linker.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described molecular glue compounds acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer.

Galapagos NV has divulged integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of ulcerative colitis and Crohn’s disease.

Arvinas Operations Inc. has identified diacylglycerol kinase-α (DGK-α) inhibitors reported to be useful for the treatment of cancer.

Chengdu Chipscreen Pharmaceutical Ltd. has synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Sunshine Lake Pharma Co. Ltd. has disclosed poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

Shenzhen Zhongge Biotechnology Co. Ltd. has identified translation initiation factor 2B (EIF2B) activators reported to be useful for the treatment of autoimmune disease, cancer, viral infection, neurodegeneration, metabolic diseases, and eye, dermatological and inflammatory disorders, among others.

Haisco Pharmaceutical Group Co. Ltd. has described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.